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RESEARCH ARTICLE
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Recent clinical trials investigating receptor tyrosine kinase (RTK) inhibitors showed a limited
clinical response in medulloblastoma. The present study investigated the role of micro-envi-
ronmental growth factors expressed in the brain, such as HGF and EGF, in relation to the
effects of hepatocyte growth factor receptor (MET) and epidermal growth factor receptor fam-
ily (ErbB1-4) inhibition in medulloblastoma cell lines. Medulloblastoma cell lines were treated
with tyrosine kinase inhibitors crizotinib or canertinib, targeting MET and ErbB1-4, respec-
tively. Upon treatment, cells were stimulated with VEGF-A, PDGF-AB, HGF, FGF-2 or EGF.
Subsequently, wemeasured cell viability and expression levels of growth factors and down-
stream signaling proteins. Addition of HGF or EGF phosphorylated MET or EGFR, respec-
tively, and demonstrated phosphorylation of Akt and ERK1/2 as well as increased tumor cell
viability. Crizotinib and canertinib both inhibited cell viability and phosphorylation of Akt and
ERK1/2. Specifically targeting MET using shRNA’s resulted in decreased cell viability. Inter-
estingly, addition of HGF to canertinib significantly enhanced cell viability as well as phosphor-
ylation of Akt and ERK1/2. The HGF-induced bypass of canertinib was reversed by addition
of crizotinib. HGF protein was hardly released bymedulloblastoma cells itself. Addition of
canertinib did not affect RTK cell surface or growth factor expression levels. This manuscript
points to the bypassing capacity of exogenous HGF in medulloblastoma cell lines. It might be
of great interest to anticipate on these results in developing novel clinical trials with a combina-
tion of MET and EGFR inhibitors in medulloblastoma.
Introduction
Medulloblastoma is the most common malignant pediatric brain tumor and accounts for
approximately 15–20% of all pediatric brain tumors[1]. The 5-year event free survival of
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medulloblastoma patients has increased to approximately 80% in the average-risk group and
50–60% in the high-risk group. Treatment consists of a combination of neurosurgery, cranio-
spinal radiotherapy and chemotherapy, often resulting in long-term neurological and psycho-
logical side effects in the majority of survivors[2–5]. Specifically targeting the tumor cells with
novel therapies might improve survival as well as decrease the long-term side effects.
Transcriptional profiling studies in medulloblastoma identified four distinct molecular sub-
groups based upon clustering of genes that activate key signaling pathways involved in tumor
cell survival and proliferation: Wingless (Wnt)-subgroup (~10%), Sonic Hedgehog (SHH)-sub-
group (~30%), Group 3 (~25%) and Group 4 (~35%)[6,7]. These subgroups have distinct tran-
scriptional and genetic profiles, patient demographics and clinical behavior. In the activation
of signaling pathways the tumor microenvironment also plays an important role. Various
receptor tyrosine kinases (RTK’s) are expressed in medulloblastoma, including vascular endo-
thelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor α
(PDGFRα), hepatocyte growth factor receptor (MET) and epidermal growth factor receptor 2
(ErbB2)[8]. Important growth factors present in the central nervous system include VEGF,
PDGF, HGF, FGF and EGF[9–13]. These growth factors can activate specific RTK’s on the
tumor cell surface. Phosphorylation of RTK’s generates a cascade of signals through common
critical downstream signaling pathways involved in cell survival and proliferation, e.g. MAPK/
ERK and PI3K/Akt pathways[8]. With kinome profiling we previously observed kinase-
induced phosphorylation of peptide sequences derived from different RTK’s in medulloblas-
toma patient samples. These RTK’s include MET and ErbB2[14]. High expression levels of
MET and ErbB2 are correlated with poor clinical outcome in medulloblastoma patients[15,16].
ErbB2 is unable to bind any known ligand and needs heterodimerization with other ErbB
receptor family members (EGFR, ErbB3, ErbB4) for activation of its intracellular kinase
domain. Therefore, MET and all ErbB family receptors might be interesting targets for the
treatment of medulloblastoma patients with RTK inhibitors.
Currently, numerous RTK inhibitors have been developed ready for use in pediatric clinical
trials. MET inhibitor crizotinib is currently being assessed for its anti-tumor activity in a pedi-
atric clinical trial, including medulloblastoma (NCT00939770). In addition, ErbB TK inhibitors
(lapatinib and erlotinib) have already been used in phase I/II clinical trials analyzing their anti-
tumor activity in children (NCT00095940; NCT00077454). ErbB TK inhibitors were well toler-
ated, but more importantly, showed a limited clinical response in medulloblastoma patients
[17,18]. A potential mechanism of tumor resistance against RTK inhibitors was found in non
small-cell lung cancer (NSCLC) and HER2-positive breast cancer, where tumors became resis-
tant to EGFR inhibition as a consequence of MET gene amplification[19,20]. Furthermore, var-
ious mutated or amplified cancer cell lines with kinase-dependency were able to bypass the
growth-inhibitory effects of specific RTK inhibitors after addition of growth factors usually
secreted by the tumor microenvironment[21–23]. Although various growth factors are present
in the central nervous system, the role of microenvironmental growth factors in relation to the
effects of specific RTK inhibitors in medulloblastoma needs to be elucidated further.
The present study examines the role of microenvironmental growth factors in relation to
the effects of RTK inhibitors crizotinib and canertinib on tumor cell viability and downstream
signaling in medulloblastoma cell lines.
Materials and Methods
Cell cultures and treatments
Human medulloblastoma cell line DAOY was purchased from the American Type Culture
Collection (ATCC), human medulloblastoma cell lines RES256, UW402, UW426 and UW473
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were a kind gift of Dr Michael S. Bobola, (Seattle Children’s Hospital Research Institute)[24].
Medulloblastoma cell lines were cultured in DMEM/F12 growth medium at 37°C in a humidi-
fied atmosphere of 5% CO2. Growth medium was supplemented with 5% fetal calf serum
(FCS) (GIBCO) 100 units ml-1 penicillin and 100μg ml-1 streptomycin (GIBCO). Cells were
treated with RTK inhibitors crizotinib, a dual inhibitor of MET and ALK, and canertinib, tar-
geting the ErbB receptor family (EGFR, ErbB2 and ErbB4) (LC laboratories, Woburn, MA,
USA)[25,26]. Cells were stimulated with growth factors, including VEGF-A, PDGF-AB, HGF,
FGF-2 and EGF (up to 100ng/ml, Life Technologies).
Flow cytometry analyses
Cells were treated with or without crizotinib or canertinib for one day. Cells were harvested
by trypsinization, washed and blocked by PBS 1% Bovine Serum Albumin (BSA) (Sigma, St
Louis, MO, USA) and stained with anti-VEGFR-1 (#MAB321, Sigma Aldrich), anti-VEGFR-2
(#V9134, Sigma Aldrich), anti-VEGFR-3/APC (#FAB3492, R&D systems, Minneapolis, MN,
USA), anti-PDGFRα/biotin (#13-1401-80, eBiosciences, Vienna, Austria) and anti-PDGFRβ/
PE (#558821, BD Biosciences), anti-MET/FITC (#FAB3582, R&D systems), anti-FGFR-1
(#91740, Cell Signalling, Danvers, MA, USA), anti-FGFR-2 (#MAB684, R&D systems), anti-
EGFR (#ab231, Abcam, Cambrigde, UK), anti-ErbB2/PE (#FAB6744, R&D systems), anti-
ErbB3/APC (#FAB3481, R&D systems) and anti-ErbB4 (#MAB11311, R&D systems). Primary
VEGFR-1, VEGFR-2, FGFR-2 and ErbB4 antibodies were visualized using rabbit anti-mouse
PE-conjugated secondary antibody (Dako Cytomation, Glostrup, Denmark) and FGFR-1
using FITC-conjugated swine anti-rabbit secondary antibody (Dako Cytomation). Primary
EGFR was visualized using Alexa Fluor 488 conjugated anti-rat secondary antibody and
PDGFRα was visualized using streptavidin/FITC (BD Biosciences). IgG-FITC/PE/APC and
secondary antibodies were used as negative (isotype) controls. Expression was analyzed using
FACScalibur1 (BD CellQuest Pro software, BD Bioscience). The data were analyzed using
FlowJo software (Tree Star Inc., Ashland, Oregon, USA). Expression levels were considered as
actual membrane protein expression when the percentage of RTK expressing cells reached 5%
above its isotype control.
Cell count and viability assays
Quantification of medulloblastoma cell count and cell viability was performed using crystal
violet staining andWST-1 colorimetric viability assays. Cells were seeded in sextuple in a
96-well plate at a density of 15 x 103 cells/well in DMEM/F12 containing 1% FCS. After adhe-
sion cells were treated with crizotinib (0–9 μM) or canertinib (0–9 μM). After 1 hour of inhibi-
tor treatment, cells were stimulated with growth factors (all 100ng/mL). To determine the
single effect of growth factors on tumor cell count after 48h, cells were fixed with 8% formalde-
hyde for 20 minutes. Cells were washed followed by incubation with 0.04% crystal violet in 4%
ethanol for 30 minutes. Cells were then washed, air dried and incubated with 1% SDS solution
on a shaker for 1h. Optical density was measured at 595nm with a microplate reader (Bio-Rad,
Hercules, CA, USA) and tumor cell count was calculated using an internal calibrator. To exam-
ine the effects of RTK inhibitors on tumor cell viability with or without growth factor stimula-
tion, WST-1 colorimetric viability assays were used following manufacturer’s (Roche) protocol
guidelines. Optical density was measured after 48h using a microplate reader at 450 nm (Bio-
Rad, Hercules, CA, USA). Optical densities were subtracted by a blank control and were nor-
malized in percentages relative to control-treated cells (100%). Effects of growth factors on
tumor cell viability were plotted against inhibitor concentrations. Area Under the Curve
(AUC) was calculated between inhibitor-treated cells with the addition of growth factor
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(AUCinh+gf) relative to inhibitor-treated cells only (100%) (AUCinh). Bypass of the effect of the
RTK inhibitor on tumor cell viability was defined by the following equation:
ððAUCinhþgf AUCinhþgf stdevÞ  ðAUCinh þ AUCinh stdevÞÞ  0
AUCinh + gf = AUC of cells treated with inhibitor and growth factor
AUC inh + gf stdev = Standard deviation of the AUC of cells treated with inhibitor and growth
factor
AUCinh = AUC of cells treated with inhibitor alone
AUCinh stdev = Standard deviation of the AUC of cells treated with inhibitor alone
Western blot analyses
To examine protein levels, 1 x 106 cells were plated in T25 flasks in 5 mL DMEM/F12 contain-
ing 1% FCS. After adhesion cells were treated with optimal dosages of crizotinib (9 μM) or
canertinib (9 μM) based on cell viability assays using different concentrations of inhibitor.
Combined treatment consisted of crizotinib (9 μM) + canertinib (4 μM) or canertinib (9 μM)
+ crizotinib (4 μM). To detect RTK phosphorylation, different concentrations of growth factor
(1–100ng/mL HGF or EGF) were added for 5 minutes after 1h of inhibitor treatment. For the
detection of downstream signaling effectors, growth factor (100ng/mL HGF or EGF) was
added for 1h after 1h of inhibitor treatment. Cells were lysed in laemmli sample buffer (Bio-rad
laboratories). Proteins were separated by sodium-dodecyl sulfate–polyacrylamide gel electro-
phoresis (SDS-PAGE), and transported onto nitrocellulose membranes. Membranes were
incubated overnight using monoclonal antibodies (dilution: 1:1000) for phospo-Erk (pERK1/
2)(#9101), total ERK1/2 (tERK1/2)(#9102), phospho-Akt (S473) (pAkt)(#9271), total Akt
(tAkt)(#9272), phospo-MET (pMET)(#3126), total MET (tMET)(#4560), phospho-EGFR
(pEGFR)(#2234) and total EGFR (tEGFR)(#2232). β-actin (dilution: 1:10000) (#sc-47778,
Santa Cruz Biotechnology, Heidelberg, Germany) was used as a loading control. Membranes
were then incubated for 1 hour using HRP-conjugated secondary antibodies (Dako Cytoma-
tion). Proteins were visualized by chemiluminescence, on x-ray film, and scanned. Immuno-
blots were quantified using ImageStudio™ Lite software (Li-Cor Biosciences, Nebraska, USA)
Antibody array kits
Human phospho-kinase antibody arrays (R&D Systems) and human growth factor antibody
arrays (Abcam) included membranes containing multiple protein antibodies printed in dupli-
cates to measure protein expression levels. 4 x 10^6 cells were plated in T75 flasks in 10 mL
DMEM/F12 containing 1% FCS. After adhesion cells were stimulated with growth factor
(100ng/mL HGF or EGF) for 1h, treated with crizotinib or canertinib for 1 day or lysed. All
lysates were prepared according to manufacturer’s protocols and sample protein concentra-
tions were determined by a bicinchoninic acid (BCA)-protein quantification assay (Pierce).
The protein intensity spots were visualized by chemiluminescence, on an x-ray film, and
scanned. Signal intensities of proteins were analyzed with array software (ScanAlyze, Eisen
Software, http://rana.lbl.gov/eisen). Data normalization was conducted by subtraction of the
mean array background intensity from the protein signal intensities of each individual spot.
For the human phospho-kinase antibody kit, mean signal intensities of individual proteins
from growth factor-treated cells were then subtracted by the mean signal intensities of individ-
ual proteins from the control cells. For the human growth factor antibody array kit, mean sig-
nal intensities of individual proteins were normalized to a control.
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MET knockdown experiment
RES256 and UW473 cells were stably transduced with mCherry coupled pLKO.1 Mission
shRNA vectors (Sigma-Aldrich, Zwijndrecht, the Netherlands) against MET (shMET) using
Fugene HD Transfection Reagent (Roche, Woerden, the Netherlands) according to the manu-
facturer’s instructions. A scrambled vector (shSCR) was used as a vector control. Four days
after transduction, transduction efficiency and knockdown was confirmed by measuring
mCherry and MET cell surface expression levels by means of flow cytometry analysis. On the
same day (Day 4), cells were seeded in sextuple in a 96-well plate at a density of 2 x 103 cells/
well in DMEM/F12 containing 5% FCS. Cells were counted on day 5, 7, 9 and 11, using crystal
violet staining as described above.
Statistics
Effects of growth factors on tumor cell count and quantifications of western blots were com-
pared using a student’s t-test. Different conditions in cell viability assays and western blots
were compared, by grouping all medulloblastoma cell lines. Subsequently, a nonparametric wil-
coxon matched-pairs signed ranks test was used for inter-group comparison between condi-
tions. SPSS20 was used for statistical analysis and a confidence level of p< 0.05 was considered
to be significant.
Results
MET and EGFR are highly expressed on cell surface of
medulloblastoma cell lines
Important growth factors that are present in the central nervous system include VEGF, PDGF,
HGF, FGF and EGF[9–13]. We expected that these growth factors influence cell signaling by
binding to their RTK’s on the tumor cell surface leading to tumor cell proliferation. Therefore,
we started to screen the expression of VEGFR1-3, PDGFRα/β, MET, FGFR1-2 and ErbB1-4 on
the cell surface of 5 medulloblastoma cell lines (Fig 1 and S1 Fig). Flow cytometry analysis
revealed that MET (mean±sd: 74.9% ± 13.9%), EGFR (mean±sd: 77.4% ± 10.9%) and ErbB2
(mean±sd: 67.8% ± 10.3%) are highly expressed in all medulloblastoma cell lines, whereas
ErbB3 (mean±sd: 4.0% ± 3.6%) and ErbB4 (mean±sd: 1.5% ± 2.1%) are barely expressed at all
(Fig 1 and S1 Fig). Variable expression was observed for VEGFR1, VEGFR3 and PDGFRβ,
whereas VEGFR2, PDGFRα, FGFR1, FGFR2 were barely expressed at all (Fig 1). Since ErbB2
is unable to bind any known ligand and needs heterodimerization with other ErbB receptor
family members (EGFR, ErbB3, ErbB4) for activation of its intracellular kinase domain, we fur-
ther focused on the highly expressed and clinically relevant MET and EGFR receptors.
HGF and EGF phosphorylate MET and EGFR, respectively
Next, we examined the effects of exogenous growth factor stimulation and RTK inhibition on
phosphorylation of MET and EGFR in cell lines RES256 and UW473. These cell lines were
selected based on their high MET and EGFR cell surface expression compared to the other cell
lines. Potential interesting RTK inhibitors that target MET or EGFR are crizotinib and canerti-
nib, respectively. Stimulation with different concentrations of HGF (1–100ng/mL) resulted in
the highest phosphorylation of MET at 100ng/mL in both cell lines (Fig 2A and 2C). When cri-
zotinib was added to the cells, HGF stimulation resulted in a decreased phosphorylation of
MET in both cell lines (Fig 2A and 2C). In the same way, EGF stimulation (1–100ng/mL)
resulted in highest phosphorylation of EGFR in both cell lines at 100ng/mL, which was
decreased when canertinib was added previously (Fig 2B and 2D). These results indicate that
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HGF and EGF phosphorylate their receptors MET and EGFR at 100ng/mL, which can be
blocked with the RTK inhibitors crizotinib and canertinib, respectively. Based upon these
results, we continued these experiment by using consequent identical levels of HGF and EGF
(both 100ng/mL).
Downstream signaling proteins activated by HGF, included ERK1/2, c-Jun, p38a and Akt
(S473). A decrease in phospho-protein expression was found for CREB in RES256 cells (Fig 2E
and S2 Fig). In cell line UW473, a HGF induced increase in phospho-protein expression of
ERK1/2, RSK1/2/3, Akt (S473), AMPKA1 and AMPKA2. Downregulated phospho-proteins in
UW473 cells included WNK1, CREB, c-Jun, p38a and PRAS40 (Fig 2E, S2 Fig and S3 Fig).
Stimulation with EGF increased phospho-protein expression of EGFR, ERK1/2, RSK1/2/3,
MSK1/2, c-Jun, p38a, STAT3 (Y705), Akt (T308), Akt (S473), GSK-3a/b, AMPKA1 and
AMPKA2 in RES256 cells (Fig 2F, S2 Fig and S3 Fig). EGF stimulation of UW473 cells
increased phospho-protein expression of EGFR, ERK1/2, RSK1/2/3, WNK1, CREB, c-Jun,
p38a, Akt (S473) and PRAS40 (Fig 2F, S2 Fig and S3 Fig). Altogether, these results indicate that
EGF and HGF commonly activate critical downstream signaling effectors, including Akt and
ERK1/2 signaling proteins.
Exogenous HGF significantly bypasses the effect of ErbB inhibition on
tumor cell viability in medulloblastoma cell lines
Tumors might circumvent the effects of kinase inhibitors due to the presence of microenviron-
mental RTK ligands, such as VEGF, PDGF, HGF, FGF and EGF. The single effect of stimula-
tion with the above mentioned growth factors on tumor cell count are given in Fig 3A–3E.
Fig 1. Cell surface RTK expression levels in medulloblastoma cell lines.Heatmap showing the cell surface expression levels of various RTK’s in
percentages using flow cytometry analyses in medulloblastoma cell lines. Viable cells were stained with fluorescently labeled RTK-specific antibodies or
isotype control antibody. Numbers represent the percentage of RTK-expressing cells, reaching above their isotype controls.
doi:10.1371/journal.pone.0141381.g001
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Fig 2. HGF and EGF phosphorylate MET and EGFR, respectively. A-B Immunoblots, showing the effects of A HGF stimulation (0-100ng/ml) in
combination with crizotinib on MET (MET: 145kDa, pro-MET: 170kDa) phosphorylation andB EGF stimulation (0-100ng/ml) in combination with canertinib on
EGFR (175kDa) phosphorylation in cell lines RES256 and UW473. Bands of MET represent MET (145kDa) and pro-MET (170kDa). Total-MET and total-
EGFR were used as loading controls. C-DQuantification analysis of immunoblots showing theC normalized phospho-MET expression and D normalized
phospho-EGFR expression. Quantitations are representative of 2 to 3 independent experiments. Student’s t-test: *p<0.05. E-FQuantitative analysis of the
effects of E HGF and F EGF using human phospho-kinase arrays in cell lines RES256 and UW473. The plot displays the phosphorylation sites of the
proteins present on the proteome array that are categorized upon different signal transduction pathways. Mean pixel intensities were calculated and
HGF Bypasses ErbB Inhibition on Cell Viability
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Medulloblastoma cell lines are most sensitive to exogenous HGF (4 out of 5 cell lines), FGF-2
(3 out of 5 cell lines) and EGF (3 out of 5 cell lines) resulting in increased tumor cell growth.
Less sensitivity is observed for stimulation with VEGF-A and PDGF-AB. To investigate
whether medulloblastoma cell lines release the above mentioned RTK ligands, we used a
human growth factor antibody array kit. We observed that overall growth factor production
was low in medulloblastoma cell lines, except for FGF-2 (Fig 3F). Since we did not detect
FGFR1-2 cell surface expression, we continued our focus on MET and EGFR receptors. The
single effects of crizotinib and canertinib on tumor cell viability are given in Fig 4A and 4B. We
observed a dose-dependent decrease in tumor cell viability in all used medulloblastoma cell
lines after treatment with either crizotinib (LC50 mean±sd: 5.0 μM ± 1.9 μM) or canertinib
(LC50 mean±sd: 4.7 μM ± 1.5 μM).
The difference in tumor cell viability as a consequence of the addition of growth factors to a
RTK inhibitor was calculated by the difference in area under the curve (AUC), depicted by the
grey area in Fig 4C. The calculated differences in AUC for all growth factors used in combina-
tion with crizotinib or canertinib are shown in Fig 4D–4M. Upward lines marked with an aster-
isk indicate bypass of the effect of the RTK inhibitor on tumor cell viability by the addition of a
growth factor. Whereas VEGF-A, PDGF-AB, FGF-2 and EGF show weak bypassing potential
in addition to either crizotinib or canertinib, addition of HGF shows strong bypassing potential
by significantly bypassing the growth-inhibitory effects of canertinib in medulloblastoma cells
(Fig 4D–4M).
subtracted by the mean background intensity of the array. Bars depict the difference between growth factor-stimulated cells and control cells. Positive values
indicate growth factor-induced phosphorylation of the kinase.
doi:10.1371/journal.pone.0141381.g002
Fig 3. Effects of the addition of growth factors on tumor cell count in medulloblastoma cell lines. A-E Barplots, showing the effects of A VEGF-A, B
PDGF-AB, C HGF,D FGF-2 and E EGF on cell count after 48h using crystal violet staining. Tumor cell count was calculated using an internal calibrator.
Experiments were performed in sextuple. F Barplot, showing the protein expression levels of VEGF-A, PDGF-AB, HGF, FGF-2 basic and EGF in 5
medulloblastoma cell lines. Mean signal intensities of individual growth factors were normalized to a medium control. *p<0.05, **p<0.01
doi:10.1371/journal.pone.0141381.g003
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Combined RTK inhibition blocks HGF-enhanced downstream signaling
and tumor cell viability
We continued by combining specific RTK inhibitors to overcome the growth factor-induced
bypass mechanism. Cell viability results demonstrated that addition of EGF to crizotinib
Fig 4. HGF significantly increases tumor cell viability in canertinib-treatedmedulloblastoma cell lines. Cell viability assays, showing the effects of
different concentrations of A crizotinib andB canertinib on tumor cell viability in 5 medulloblastoma cell lines after 48h.C Cell viability assay, showing the
effect of exogenous HGF in addition to canertinib on tumor cell viability in cell line UW473. The difference in area under the curve (AUC) is depicted by the
grey area. D-MCell viability assays showing the effects of exogenous VEGF-A, PDGF-AB, HGF, FGF-2 and EGF in addition to crizotinib or canertinib in
medulloblastoma cell lines. Cells were stimulated with growth factor after 1h of RTK inhibition for 48 hours. Lines depict the relative AUC in percentages
between inhibitor and growth factor-treated cells and inhibitor-treated cells only (100%). Asterisks indicate enhanced tumor cell viability and was defined by
an increase in the relative AUC after subtraction of the standard deviations of all data points of both curves. A nonparametric wilcoxon matched-pairs signed
rank test indicated significantly enhanced cell viability (*p<0,05) between HGF-stimulated cell lines compared to non-HGF stimulated medulloblastoma cell
lines during canertinib treatment.
doi:10.1371/journal.pone.0141381.g004
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showed no significant increase in cell viability and so no difference was seen when canertinib
was added to decrease EGF-induced effects on cell survival (Fig 5A). In western blots, EGF
Fig 5. Combined RTK inhibition blocks HGF-enhanced downstream signaling and tumor cell viability. A-B Cell viability assays showing the effects of
combined treatment with crizotinib and/or canertinib in medulloblastoma cell lines relative to single treatment in addition to A EGF or B HGF after 48 hours.
Lines depict the percentage AUC of growth factor in addition combined RTK inhibition relative to growth factor in addition to single RTK inhibition (100%). A
nonparametric wilcoxon matched-pairs signed rank test indicated significantly enhanced tumor cell viability (*p<0,05) between HGF-stimulated cell lines
compared to non-HGF stimulated medulloblastoma cell lines in addition to canertinib. C-D Immunoblots showing the effects of C EGF andD HGF during
single and combined treatment with crizotinib and/or canertinib on downstream signaling effectors Akt (S473) (60kDa) and ERK1/2 (44 kDa,42 kDa). β-actin
was used as a loading control. Growth factors were added after 1 hour of inhibitor treatment. Lysates were made after 2 hours of inhibitor treatment.
doi:10.1371/journal.pone.0141381.g005
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addition showed increase of phospho-Akt and phospho-ERK1/2, whereas this effect was
reversed by addition of canertinib (Fig 5C).
In Fig 5B, HGF in addition to canertinib demonstrated significantly increased cell viability
in the cell cultures, whereas the HGF enhanced cell viability was reversed by the addition of cri-
zotinib. Accordingly, western blots showed increased phospho-Akt and phospho-ERK1/2
upon HGF addition, whereas this effect was reversed by addition of crizotinib (Fig 5D).
The above results suggest that exogenous HGF could be a key player in bypassing the effects
of kinase inhibitors in medulloblastoma cells. To understand more about the mechanism of
HGF/MET-induced bypass, we investigated the expression of the previously analyzed set of
RTK’s on the cell surface of RES256 and UW473 cells upon treatment with crizotinib or caner-
tinib. Treatment with crizotinib or canertinib had no effect on cell surface RTK expression lev-
els compared to control-treated cells (Fig 6A and 6B). Moreover, we analyzed growth factor
production in the absence or presence of crizotinib or canertinib and could conclude that the
growth factor production in RES256 and UW473 cells did not differ upon addition of crizoti-
nib or canertinib (Fig 6C and 6D). Since crizotinib is a dual inhibitor of MET and ALK, we
used shRNA’s targeting MET to knockdown MET gene expression to be sure the crizotinib-
induced decrease in cell viability was due to a blockade of MET. We could effectively knock-
down MET in RES256 and UW473 cells using shRNA’s targeting MET (S4 Fig). Knockdown
of MET resulted in decreased cell viability (Fig 6E and 6F), suggesting that MET is critical in
the growth and survival of medulloblastoma cells. Altogether, these data indicate that the avail-
ability of exogenous HGF is of key importance in bypassing the growth-inhibitory effects of
RTK inhibitors through activation of highly expressed MET
Discussion
The present study demonstrates that exogenous HGF can significantly bypass the growth-
inhibitory effects of canertinib in medulloblastoma cell lines. Previously with kinome profiling,
we observed MET and EGFR/ErbB2 peptide activity in primary medulloblastoma samples[14].
In this study, RTK inhibitors crizotinib and canertinib were used to inhibit these targets,
respectively. Tumor cell viability and downstream signaling were inhibited upon the single use
of these inhibitors. The present study investigated the bypass potential of ligands commonly
expressed in the brain tumor’s micro-environment.
MET was expressed on the cell surface of our medulloblastoma cell lines. This result is con-
sistent with previous studies in medulloblastoma cell lines and primary tissue[15,27]. Further-
more, we show that EGFR and ErbB2 are highly and ErbB3 and ErbB4 are hardly expressed on
the cell surface of our medulloblastoma cell lines. Expression of EGFR and ErbB2 is in agree-
ment with previous studies in medulloblastoma cell lines and primary tissue expression, in
which expression of EGFR and ErbB2 was detected in varying percentages[28]. More interest-
ingly, high expression levels of both MET and ErbB2 in primary medulloblastoma tissue are
correlated with poor clinical outcome in patients[15,16]. Therefore, MET and ErbB family
receptors are interesting targets for RTK inhibitors in the treatment of medulloblastoma
patients.
The anti-proliferative effects of crizotinib in our study underscores previous reports analyz-
ing the anti-proliferative effects of MET TK inhibitors in medulloblastoma cell lines and
mouse xenograft models[27,29,30,31]. Crizotinib is currently being assessed in pediatric clini-
cal trials including medulloblastoma (NCT00939770). Although investigation of anti-tumor
activity is still in progress, crizotinib was well tolerated in medulloblastoma patients[32]. In
addition, administration of canertinib effectively inhibited cell viability in our medulloblastoma
cell lines. These results are compatible with a previous study analyzing the effects of gefitinib
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(EGFR TK inhibitor) in medulloblastoma cell lines and xenografts[33]. To investigate whether
ErbB family receptor inhibition could improve the clinical outcome of brain tumor patients,
the use of single EGFR/ErbB2 TK inhibitors was analyzed for its anti-tumor activity in various
clinical trials. EGFR/ErbB2 TK inhibitors were well tolerated, but more importantly, showed
limited clinical response in brain tumor patients including patients with medulloblastoma
(NCT00095940; NCT00077454)[17,18]. The contrasting results of pre-clinical medulloblas-
toma models and clinical trials might be explained by the fact that pre-clinical in vitro models
often lack the natural tumor environment.
An emerging concept is the role of the tumor microenvironment in bypassing targeted ther-
apies by producing ligands that can compensate for the drug-inhibited TK by phosphorylating
alternative RTK’s. Growth factors, such as VEGF, PDGF, HGF, FGF and EGF are normally
expressed during brain development. High expression levels of these growth factors were previ-
ously found in brain tumor bulk [9–13]. It is important to take into consideration that these
results of crude tissue might have no relation with growth factors present on the cellular level,
where mechanisms of bound and soluble growth factors play a crucial role in relation to spe-
cific stromal crosstalk. A limitation of the present study is that a certain amount of growth fac-
tor was added, whereas the exact amount present for interference with RTKs on a cellular level
is still unknown. We are not aware of any possibility or study measuring exact growth factor
availability on the cellular level. Therefore, different concentrations of growth factor were used
to define the optimal dose for RTK phosphorylation in medulloblastoma cell lines based upon
previous studies[22,23,34].
In our study, addition of the above mentioned growth factors to crizotinib or canertinib
highlights the strong bypassing potential of HGF in addition to canertinib on medulloblastoma
cell viability and downstream signaling effectors Akt and ERK1/2. Addition of EGF to crizoti-
nib also resulted in increased Akt and ERK1/2 signaling, whereas it did not functionally affect
the cell viability. These results suggest that other signaling proteins will be involved and
counter balance the increased Akt and ERK1/2 signaling without resulting in altered cell viabil-
ity. The HGF-induced bypass of canertinib was completely reversed by co-administration of
MET inhibitor crizotinib, indicating that HGF was acting through its receptor MET. This was
underscored by the finding that targeting MET using shRNA, results in decreased cell viability
in medulloblastoma cell lines. The phenomenon of HGF/MET-induced bypass is in line with
previous reports in other tumor types. A substantial increase in HGF and/or MET expression
levels as a consequence of EGFR inhibition was shown to be responsible for the bypass of RTK
inhibition in adult glioblastoma and breast cancer[20,35]. In our study, the addition of RTK
inhibitors did not increase HGF or MET expression levels. Unlike in our medulloblastoma cell
lines, HGF is constantly produced in vivo[14,36], suggesting potential bypass mechanisms
related to the tumor micro-environment.
In conclusion, this manuscript describes the bypassing capacity of paracrine HGF in medul-
loblastoma cell lines. MET and EGFR were highly activated in primary medulloblastoma sam-
ples and subsequently high percentages of medulloblastoma cells expressed these RTK’s. Our
study highlights the extensive importance of HGF present in the tumor micro-environment in
Fig 6. Crizotinib and canertinib does not affect RTK and growth factor expression levels in medulloblastoma cell lines. A-B Barplots, showing the
cell surface expression levels of various RTK’s in MFI using flow cytometry analyses inA RES256 andB UW473 cells treated with crizotinib, canertinib or
control. Viable cells were stained with fluorescently labeled RTK-specific antibodies or isotype control antibody. Log values represent the MFI of RTK-
expressing cells, subtracted by the MFI of their isotype controls. C-D Barplots, showing the protein expression levels of VEGF-A, PDGF-AB, HGF, FGF-2
basic and EGF in C RES256 andD UW473 cell treated with crizotinib, canertinib or control. Mean signal intensities of individual growth factors were
normalized to control. E-FCell proliferation assays, showing the effect of MET knockdown on cell count in ERES256 and F UW473 cells using crystal violet
staining. Cells were seeded at day 4 after transduction for 7 days at a density of 2 x 103 cells/well in DMEM/F12 containing 5% FCS. Tumor cell count was
calculated using an internal calibrator.
doi:10.1371/journal.pone.0141381.g006
HGF Bypasses ErbB Inhibition on Cell Viability
PLOS ONE | DOI:10.1371/journal.pone.0141381 October 23, 2015 13 / 16
bypassing the effects of RTK inhibitors. These findings provide a rational explanation for the
limited efficacy of single RTK inhibitors in medulloblastoma clinical trials. Moreover, the suc-
cessful combination treatment to overcome this bypass mechanism supports the importance of
combination therapies in medulloblastoma. Further studies in vivo using animal models will
be warranted to support this hypothesis. Anticipating on these results by the development of
novel (pre-) clinical trials with specific TK inhibitors in combination with a MET inhibitor
seems very important to improve the clinical efficacy of novel targeted therapies in medullo-
blastoma in the future.
Supporting Information
S1 Fig. MET and EGFR are highly expressed on the cell surface of medulloblastoma cell
lines. Results of flow cytometry analysis, showing histograms of MET, EGFR, ErbB2, ErbB3
and ErbB4 cell surface expression levels (blue) compared to their isotype controls (red) in
medulloblastoma cell lines DAOY, RES256, UW402, UW426 and UW473. Viable cells were
stained with anti-MET, anti-EGFR, anti-ErbB2, anti-ErbB3 or anti-ErbB4 antibodies and the
percentage of RTK-expressing cells was calculated by subtraction of isotype controls.
(TIF)
S2 Fig. Effects of MET knockdown on MET expression and cell proliferation. Phospho-
kinase proteome array membranes of cell lines RES256 and UW473 showing the effects A
HGF or B EGF stimulation on downstream signaling. Phospho-proteins that showed the most
robust changes in phosphorylation are indicated by numbers that are explained underneath
the membranes.
(TIF)
S3 Fig. HGF and EGF stimulation results in Akt and ERK1/2 phosphorlyation.Western
blots showing the effects of HGF (left panel) and EGF stimulation (right panel) on phosphory-
lation of critical downstream signaling effectors Akt and ERK1/2.
(TIF)
S4 Fig. Effects of MET knockdown on MET expression and cell proliferation. A-B Results
of flow cytometry analysis, showing dotplots and histograms of MET cell surface expression in
shSCR (red) and shMET (blue) in cell lines A RES256 and B UW473.
(TIF)
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